Bayerische Motoren Werke ADR (BMWYY)

Immunotherapy has emerged as a more gentle way to treat cancer over the past few years. However, it is very expensive and results are usually inconsistent among patients, especially those suffering from solid tumors. Researchers in Hong Kong have come up with a biomaterial containing silica that can help to address the current shortcomings of immunotherapy and dramatically improve efficacy rates.

At least 40 million individuals from around the world use ChatGPT each day seeking information on health care-related topics, an analysis conducted by AI tool Knit. The report underscores how people use the technology and the need for oversight so that millions don’t get wrong information on such an important matter as their health.

Estrella Immunopharma (NASDAQ: ESLA, ESLAW) announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor, generating aggregate gross proceeds of approximately $8.0 million. The offering included the issuance of 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, together with a concurrent private placement of common warrants to purchase up to 7,594,935 additional shares, with net proceeds expected to be used for general corporate purposes and working capital as the company advances its CD19 and CD22-targeted ARTEMIS T-cell therapy programs, including lead candidate EB103. Aegis Capital Corp. acted as exclusive placement agent for the offerings.

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that Chief Executive Officer Amir Reichman will co-lead a Manufacturers Association of Israel–organized roundtable discussion titled “Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale” during HealthIL Week 2026. The session, scheduled for Jan. 19, 2026, at Expo Tel Aviv, will focus on Israel’s biopharma development and manufacturing ecosystem, including early-stage development, CMC activities, and clinical manufacturing, as well as readiness for later-stage and commercial manufacturing. The roundtable is expected to bring together representatives from government agencies, biopharma manufacturers, CDMOs, multinational pharmaceutical companies, biotech firms, and investors to examine current capabilities, structural gaps, and collaboration models shaping the sector’s future.

The U.S. House of Representatives passed a healthcare bill that didn’t include an extension of the ACA tax credits that were at the heart of the recent government shutdown. This bill now heads to the Senate for consideration.

TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme, one of the most aggressive forms of brain cancer. The study, conducted in collaboration with Michigan State University and published in the Journal of Functional Biomaterials, demonstrated that systemic delivery of TTX-MC138 successfully reached brain tumors in orthotopic glioblastoma models, significantly increased tumor cell apoptosis, and resulted in a statistically significant improvement in survival. The findings further validate TransCode’s TTX delivery platform and support the potential advancement of TTX-MC138 into future clinical evaluation for patients with glioblastoma, building on completed IND-enabling studies and existing Phase 1 clinical experience outside the central nervous system.

The World Health Organization (WHO), the agency of the United Nations responsible for overseeing matters related to global health, revealed that 2025 was marked by notable progress in ensuring populations around the world were supported to have good health. However, climate shocks, conflicts and funding cuts strained many health systems around the world and put a damper on the prospects for sustained improvements to health in the years to come.

BMW collision repair in West LA – OEM-first repairs, BMW factory-trained technicians, and exceptional customer service from a family-owned shop serving Santa Monica and the Westside since 1972.

Used trucks Riverside buyers have been searching for are now more accessible than ever as TM Motors expands its inventory of quality pre-owned vehicles. The dealership, located at 10100 Arlington Ave., continues to build its reputation for transparent pricing and customer-focused service in the competitive automotive market, offering Riverside-area buyers an enhanced selection of reliable transportation options.

December 10, the EXLANTIX ET received the highest five-star safety rating in the latest Euro NCAP (2024 protocol) assessment.

The young population faces an increasing health challenge posed by brain tumors affecting adolescents and children. While their occurrence isn’t as common as that of other cancers in this demographic group, brain cancers account for the biggest fraction of fatalities related to cancer in this group. Many questions have therefore emerged regarding whether modern screens and lifestyles play a role in the rise of brain cancer among younger people.

United States, December 25, 2025 -- As part of the UK 2026 Budget announcement, a new pay-per-mile electric vehicle tax has been introduced, set to come into effect starting in 2028. This tax represents a major shift in how electric vehicle (EV) ownership will be taxed, directly affecting many EV owners, including drivers of popular models such as the Porsche Taycan, BMW i4 with curved display, various Toyota and Lexus electric vehicles and many more. Carcode, a leading provider of mileage protection services, is calling attention to the implications of this change and offering solutions to help EV owners navigate the shifting landscape.

CarGym, a leader in high-performance aftermarket parts for European luxury vehicles, has expanded its global presence. This move strengthens the company's footprint in international markets, offering premium parts for luxury cars worldwide.

North Vancouver, BC, 24th December 2025, ZEX PR WIRE, In an era where drivers often feel uncertain about where to take their vehicles for trustworthy repairs, Bruno Automotive continues to stand as a pillar of reliability, craftsmanship, and transparency in North Vancouver. Serving the community since 1983, Bruno Automotive has

MIAMI, FL - In an industry where car accidents often lead to logistical chaos, Auto Body Lab is officially setting a new standard for automotive recovery in South Florida. Operating as a premier distributor of comprehensive collision repair and paint services, Auto Body Lab ( https://autobodylab.com/ ) bridges the gap between distressed drivers and elite, certified restoration solutions.

HealthLynked (OTCQB: HLYK) announced a strategic consulting partnership with PBACO Holding LLC, a physician-led, value-based care organization supporting more than 15,000 physicians across 26 states and managing over 400,000 patient lives. The partnership is intended to strengthen HealthLynked’s integration with large insurance payers and accelerate deployment of its AI-enabled care-coordination platform by leveraging PBACO’s expertise in value-based contracting, commercial and government ACO program design, payer relationships, and multi-state provider network operations.

Oncotelic Therapeutics (OTCQB: OTLC ) is rapidly emerging as a key player in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (“SABCS”), highlighting that its Deciparticle(TM) platform can package even the toughest, water-resistant drugs into smaller, uniform nanoparticles that are small enough for effective and safe intravenous use ( ibn.fm/LxQ7N ).

Immunotherapy, an approach that seeks to stimulate the immune system to attack and destroy cancer cells, is a new field of research that has shown remarkable results in some patients. However, the overall fraction of patients who can benefit from immunotherapy is still very low, and researchers have been looking for ways to make this treatment modality work for a lot more patients.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases where unmet medical need exists, announced extended top line results from its Phase 2a clinical trial of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. The updated findings highlight clinical improvements with an optimized gel formulation of the investigational therapy, underscoring the potential of SGX302 as a noncarcinogenic, photodynamic treatment.

A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, is developing a vaccine candidate known as RiVax(R) to protect against ricin exposure, positioning the company’s work at the center of biodefense preparedness as public awareness of ricin’s lethality grows.

Annovis Bio (NYSE: ANVS) announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued access to buntanetap for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker data to support further evaluation of buntanetap’s potential as a disease-modifying therapy for neurodegenerative disorders.

Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to explore potential collaboration involving secure artificial intelligence, advanced computing, and cybersecurity technologies that may support Nutriband’s research and long-term product development initiatives. The company said the discussions will focus on areas such as secure AI and analytics platforms for regulated pharmaceutical data, data integrity frameworks supporting abuse-deterrent technologies, and advanced modeling and simulation enabled by quantum-ready infrastructure, while emphasizing that the LOI does not establish a partnership or commercial relationship and that any future collaboration would be subject to further review, due diligence, and definitive agreements.

In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human Services. For a long time, the scientific community has struggled to find out why some individuals who got infected with Covid-19 recovered fully while others developed lingering symptoms that came to be described as long Covid. Now a new study has established that the key driver among people with long Covid could be chronic inflammation and this opens new pathways to treating the condition .

In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds.

A new study done in India has produced results that bring into question the longstanding assumption that treating cancer requires tumors to be destroyed. The researchers attained remarkable results by using another approach, treating the tumor rather than attacking it, and their approach was effective in taming the aggressiveness of glioblastoma while also toning down many biomarkers that indicate the severity of the cancer.